1 The P-blocking effect of 4 P-adrenoceptor antagonists with different pharmacokinetic properties was studied after intravenous and intraportal administration to control rats and to rats with experimental inflammation. 2 In rats with inflammation the effects of propranolol and oxprenolol, which are mainly bound to a,-acid glycoprotein (ax-AGP), were significantly less after intravenous administration, but not after intraportal administration. In contrast, for metoprolol and atenolol, which are only negligibly serum bound, no difference was observed between control rats and rats with inflammation for either route of administration. 3 Total and unbound serum concentrations of propranolol were measured 20 min after intravenous and intraportal administration. 4 After intravenous administration, in the rats with inflammation total concentrations of propranolol were more than twice, and unbound concentrations less than half those of control rats. After intraportal administration the total concentrations were 8 times, and the unbound concentrations 3 times higher in the rats with inflammation.
Introduction
Some P-adrenoceptor antagonists are mainly bound to al-acid glycoprotein (o1-AGP) in serum (Belpaire et al., 1982) and the presence ofdisease or administration of inducing agents can increase the concentration of ax-AGP and thus serum binding of such drugs (Paxton, 1983 ). The effect of increased binding on the pharmacokinetics of these drugs has been evaluated in several studies. After oral administration the serum concentrations of propranolol and oxprenolol are higher when inflammation is present, in man (Schneider et al., 1976; Kendall et al., 1979) as well as in animals (Belpaire et al., 1981; Bishop et al., 1981; Barber et al., 1983) . After intravenous administration, there is still a difference between serum concentrations of the P-adrenoceptor blockers in healthy and diseased individuals, in man (De Leve & Piafsky, 1981; Waller et al., 1982) and experimental animals (Belpaire et al., 1981; Bishop et al., 1981; Barber et al., 1983) , but it is less pronounced.
There are few reports about the effects of P-adrenoceptor antagonists in situations where their serum binding is increased. In such situations the P-adrenoceptor blocking effect of propranolol in animals was decreased after intravenous administration, but not after oral administration (Bai & Abramson, 1983; Barber et al., 1983) .
Because of the scarcity of data available in the literature, we decided to evaluate whether in the rat with inflammation, the increase in al-AGP serum concentration and the increase in binding of some Padrenoceptor antagonists, influence their P-blocking effect, and whether, for propranolol, this is related to total or unbound drug concentrations in serum.
Propranolol and oxprenolol which are bound to al-AGP, and atenolol and metoprolol which are not bound to this protein, were injected intravenously and intraportally into healthy rats and into rats with inflammation. Intraportal administration was used to mimic oral administration in the anaesthetized rat.
Preliminary results have been published elsewhere (Mugabo et al., 1984a,b Experiments were done in control rats and in rats in which inflammation was produced by intramuscular injection of turpentine oil (0.5 ml, 24 and 48 h before the experiment) (Jamieson et al., 1972) . Erythrocyte sedimentation rate was measured in all animals.
Experimental design
In the first study, isopropylnoradrenaline, dissolved in saline, was infused (0.01 g kg' min ') 3 times for 6 min, at intervals of 14 min. Ten minutes after the last infusion of isopropylnoradrenaline, one of the Padrenoceptor antagonists, dissolved in distilled water, was infused either intravenously or intraportally over 2 to 3 min according to the weight of the animal. The intravenous and intraportal doses were respectively: for atenolol 0.01 and 0.01 mg kg-'; for metoprolol 0.03 and 0.12 mg kg-'; for oxprenolol 0.003 and 0.03 mg kg-1; for propranolol 0.01 and 0.1 mg kg-'.
Ten minutes after the end of the infusion of the Padrenoceptor blockers, the same doses of isopropylnoradrenaline were again infused 3 times at intervals of 14min. The increase in heart rate with isopropylnoradrenaline at different times after the administration of a P-adrenoceptor blocker was expressed as a % of the mean increase in heart rate obtained with the 3 isopropylnoradrenaline infusions before the administration of the antagonist.
In a second study, the 13-antagonistic effect of propranolol was measured at the 20th min after intravenous (0.3 mg kg-') or intraportal (1 mg kg-') administration, again by infusion of isopropylnoradrenaline. Immediately after measuring the effect at the 20th min, a blood sample (3 ml) was taken with a Terumo plastic syringe for the determination of serum binding and total serum concentration ofpropranolol. After clotting for I h in a glass tube, the blood was centrifuged and serum stored in glass tubes at -20°C.
Binding experiments
The protein binding of propranolol was measured in vitro by equilibrium dialysis for 4h at 25°C as described previously (Belpaire et al., 1982 The erythrocyte sedimentation rate was increased significantly (P < 0.001) in the rats with inflammation (Tables 1 and 2 ). The heart rate 30 min after pithing was 240 ± 4 beats min-' (n = 40) in control rats, and 245 ± 5 beats min-' (n = 40) in rats with inflammation. The increase in heart rate at the end of the isopropylnoradrenaline infusion was 90 ± 5 in the control rats, 81 ± 4 in the rats with inflammation (mean of the 3 administrations). Intraportal administration ofa 10 times higher dose of propranolol resulted in a 50% reduction of the isopropylnoradrenaline tachycardia after 16min in the control animals and in those with inflammation, followed by a gradual recovery (Figure lb) .
Oxprenolol Intravenous administration ofoxprenolol (0.003 mg kg-') induced an effect similar to that seen with propranolol, a reduction of the isopropylnoradrenaline response to about 25% in the control animals and no effect in the animals with inflammation (Figure 2a isopropylnoradrenaline effect to about 50% was seen in both groups of rats (Figure 2b ).
Atenolol After intravenous administration ofatenolol (0.01 mg kg-'), the isopropylnoradrenaline effect was reduced to approximately 35% in both the control animals and those with inflammation ( Figure 3a) . After intraportal administration of the same dose of atenolol, a similar reduction of the isopropylnoradrenaline effect was seen, again with no difference being apparent between the control rats and the rats with inflammation (Figure 3b ). (0.3mg kg-'), the effect of isopropylnoradrenaline was decreased significantly (P< 0.001) in control rats to 10%, and in rats with inflammation to 55%.'The unbound propranolol fraction was 5 times lower ( Figure 5 , Table 1) in the rats with inflammation than in the control rats (P< 0.001), and the total propranolol concentrations were not significantly increased. The calculated unbound concentrations of propranolol were significantly reduced (P<0.01) and there was a correlation between the a-blocking effect of propranolol and the log ofthe unbound concentration of propranolol (r = 0.687; P<0.01; n = 12).
Intraportal administration Twenty minutes after intraportal administration of propranolol (1 mg kg-') there was an approximately 80% inhibition of the isopropylnoradrenaline effect in both groups of rats This study aimed to evaluate the effect of inflammation and increased binding to a1-AGP on the kinetics and effects of 0-adrenoceptor antagonists.
In the first study the pharmacological effect of four 0-adrenoceptor blockers was studied in control rats iinistration of propranolol with inflammation was, here too, markedly smaller ts and in rats with inflamthan in control rats. The total concentrations of propranolol after intravenous administration were more than doubled in the rats with inflammation, Rats with which is in agreement with results in rats with adjuvant Control rats inflammation induced arthritis Barber et al., 1983 ) and in patients with various inflammatory 0.9 ± 0.1 19.7+2.1*-diseases (De Leve & Piafsky 1981; Waller et al., 1982) .
The unbound propranolol concentrations were, 12.6 + 1.5 4.0+0.4*-however, lower in our rats with inflammation than in the control rats, and these unbound concentrations 193 ± 106 1519 ± 186***-correlated well with the P-blocking effect. De Leve & Piafsky (1981) mention a decreased area under the 17.3+± 5.6 61 9+10 4* curve for unbound drug, and relatively unaffected total drug concentrations of propranolol in patients 81 + 6 84 ± 23 with rheumatoid arthritis. According to the physiological approach to hepatic leans + s.e.mean (n = 6); drug clearance of Wilkinson & Shand (1975) changes in binding, at least if these changes do not exceed certain limits. Therefore, increased binding in itself, while altering the shape ofthe plasma concentration-time curve, is not expected to change the area )n. Propranolol and oxprenunder the curve for total drug after intravenous their serum binding increases administration. We found higher total concentrations sequence of an increased al-at the 20th min, but this could be due to an altered le metoprolol and atenolol shape of the curve without a change in the area under are only negligibly bound to the curve. Barber et al. (1983) found a higher area et al., 1982) . Propranolol, under the curve (AUC) for total drug in inflammation, )1 are drugs which are extrac-and to explain their results, one has to assume either he liver, whereas atenolol is that hepatic blood flow has decreased, or that the e urine.
unbound fraction has declined to a degree such that hepatic clearance indeed decreases (Wilkinson & on of the P-adrenoceptor Shand, 1975) . For the unbound concentrations, it is expected that increased binding leads to a decrease of the AUC and consequently a decreased pharinistration, the P-blocking macological effect. Such a decreased effect was found Lnd oxprenolol, which are in our experiments and also in the study ofBarber et al. were decreased in rats with (1983) in rats with adjuvant arthritis. inflammation. This has also been found for propranolol after intravenous administration in rats with adjuvant induced arthritis (Barber et al., 1983) . The Pblocking effect of atenolol and metoprolol, which are only weakly bound to serum proteins, was not changed by the inflammation. As the unbound concentration of a P-adrenoceptor blocker is thought to be responsible for its pharmacological effect (McDevitt et al., 1976) , these results suggest that the increase in serum binding of oxprenolol and propranolol in our rats with inflammation, was responsible for the decrease in pharmacological effect. This was evaluated in a second study.
In the second study the decrease by propranolol of the effect of isopropylnoradrenaline was more pronounced than in the first study, due to the higher dose of the antagonist used. The effect of propranolol in rats Intraportal administration of the P-adrenoceptor blockers After intraportal administration the P-blocking effect of the four drugs as a function oftime, was not altered by inflammation. This was also found by Barber et al. (1983) for propranolol in rats with adjuvant induced arthritis. This suggests that the unbound concentrations ofpropranolol and oxprenolol were not changed by inflammation. It should be mentioned that the doses ofmetoprolol, oxprenolol and propranolol used after intraportal administration had to be much higher than after intravenous administration, due to the important first pass effect.
In the second study, where we measured the Pblocking effect of propranolol, together with its total and unbound concentrations after intraportal administration, there was, as in the first study, no significant difference in the inhibition of the effect of isopropylnoradrenaline between the control rats and the rats with inflammation. The total propranolol concentrations after intraportal administration were about eight times higher in the rats with inflammation, and this is in agreement with the results in rats with adjuvant induced arthritis Barber et al., 1983) and in patients with inflammatory diseases (Kendall et al., 1979; Schneider et al., 1979; ; the unbound propranolol concentrations were also significantly higher. There was no significant correlation between the percentage inhibition of isopropylnoradrenaline activity and unbound concentration after intraportal administration, which contrasts with the situation after intravenous administration. This could be because we used a supramaximal dose, or due to the presence of an active metabolite, 4-hydroxypropranolol, which can be formed after intraportal administration (Paterson et al., 1970) . Our results after intraportal administration and those in the literature agree with the theoretical predictions which can be made when using a physiological approach to drug clearance. The observation that after oral or intraportal administration the area under the curve for total drug increases much more than after intravenous administration, can be explained by the fact that for high extraction drugs, extraction decreases and bioavailability increases with increased binding. The area under the curve for unbound drug should not change much when binding increases, and consequently the pharmacological effect in the two groups ofrats should not be different.
The finding that the effect ofintraportal administration of metoprolol, a drug which undergoes substantial first pass extraction and which is not bound to a,-AGP, is not influenced by inflammation, suggests that there are probably no important changes in intrinsic clearance of the P-adrenoceptor antagonists in this state, although in rats with inflammatory disease the metabolism of some drugs is impaired (Whitehouse & Beck, 1973) .
Our results show that the increase in serum binding of the P-adrenoceptor blockers induced by inflammation is accompanied by a higher total drug concentration, lower unbound concentration and a smaller pharmacological effect after intravenous administration. However, after intraportal administration, the total drug concentration is increased considerably and the unbound concentration increased to a lesser extent, but the P-blocking effect remains unchanged when serum binding is increased by inflammation.
Hence, these findings demonstrate that for P-adrenousceptor blockers mainly bound to cx,-AGP, one should consider unbound drug concentrations in the design of dose regimens for use in diseases where the binding of these drugs is altered.
